Linn Energy LLC (NASDAQ:LINE) is down more than 5% in pre-market to $0.45 after major oil producers failed to reach an agreement regarding a production freeze. This oil drop comes following a wave of optimism yesterday due to speculation that oil giants Saudi Arabia and Russia had completed a deal to stagnate oil product to stabilize oil supply. While this was welcomed news because oil prices have been in limbo for nearly two years due to an oversupply and decreasing demand, the Oil Minister of Saudi Arabia quickly dismissed the deal, leading to doubt that such a deal will be reached at all. According to TipRanks, all 5 analysts who have rating the oil giant in the last 3 months are bearish on the stock.

Repros Therapeutics Inc (NASDAQ:RPRX) is soaring nearly 60% to $1.30 in pre-market trading after the company released positive data last night on Proellex, a pipeline drug that treats symptoms associated with uterine fibroids and endometriosis. The company reported Phase 2b data yesterday evening indicating that both doses of 6mg and 12mg of Proellex achieved “significant reduction in excessive menstrual bleeding” in a study of 42 women. Furthermore, the study demonstrated a statistically significant reduction in fibroid size. Repros management plans to request a meeting with the FDA to discuss plans for the next phase of testing. According to TipRanks, 1 analyst is neutral on the stock with a $2 price target.

JPMorgan Chase & Co. (NYSE:JPM) spiked over 3% in pre-market after the company posted stronger than expected first quarter earnings this morning. The company posted EPS of $1.35 and revenue of $24.08, down year-over-year from $1.45 and $24.82 billion, respectively. However, both figures beat the analyst EPS consensus of $1.26 and revenue consensus of $23.4 billion, proving that the bank was able to manage the headwinds of flailing oil prices and macroeconomic challenges. According to TipRanks, 8 analysts currently recommend buying JPM while 1 is neutral. The average 12-month price target between these 9 analysts is $71.78, marking a 21% potential upside from current levels.

Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) is up over 23% in pre-market trading as the company received EU approval to market Sinodux. The treatment is indicated for use in nasal irrigation to moisturize around the nose. This appears commonly with chronic sinusitis, which effects 146 out of every 1,000 people in the US. The company is currently discussing options for partnerships in Europe to help distribute the product. According to TipRanks, only 1 analyst currently covers the stock with a bullish rating and a $3 price target, marking a 222% potential upside from current levels.